- Home
- MRNA vs KNSL Comparison
MRNA vs KNSL Comparison
Compare MRNA & KNSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRNA | KNSL |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 8.8B |
| IPO Year | 2018 | 2016 |
Fundamental Metrics
Financial Performance| Metric | MRNA | KNSL |
|---|---|---|
| Price | $27.57 | $355.86 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 10 |
| Target Price | $33.91 | ★ $483.78 |
| AVG Volume (30 Days) | ★ 9.9M | 214.9K |
| Earning Date | 11-06-2025 | 10-23-2025 |
| Dividend Yield | N/A | ★ 0.19% |
| EPS Growth | N/A | ★ 16.09 |
| EPS | N/A | ★ 20.35 |
| Revenue | ★ $2,232,000,000.00 | $1,802,839,000.00 |
| Revenue This Year | N/A | $19.56 |
| Revenue Next Year | $0.77 | $7.74 |
| P/E Ratio | ★ N/A | $17.52 |
| Revenue Growth | N/A | ★ 18.10 |
| 52 Week Low | $22.28 | $352.45 |
| 52 Week High | $48.92 | $531.79 |
Technical Indicators
Market Signals| Indicator | MRNA | KNSL |
|---|---|---|
| Relative Strength Index (RSI) | 60.85 | 30.53 |
| Support Level | $23.92 | $377.20 |
| Resistance Level | $26.00 | $381.81 |
| Average True Range (ATR) | 1.29 | 11.65 |
| MACD | 0.32 | -0.67 |
| Stochastic Oscillator | 99.82 | 8.42 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About KNSL Kinsale Capital Group Inc.
Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.